Korean Journal of Radiology

  • 제24권5호
  • /
  • Pages.384-394
  • /
  • 2023
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer

  • Jee Hyun Ahn (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Jieon Go (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Suk Jun Lee (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Jee Ye Kim (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Hyung Seok Park (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Seung Il Kim (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Byeong-Woo Park (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine) ;
  • Vivian Youngjean Park (Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine) ;
  • Jung Hyun Yoon (Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine) ;
  • Min Jung Kim (Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine) ;
  • Seho Park (Division of Breast Surgery, Department of Surgery, Yonsei University College of Medicine)
  • 투고 : 2022.08.27
  • 심사 : 2023.03.10
  • 발행 : 2023.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Mammographic density is an independent risk factor for breast cancer that can change after neoadjuvant chemotherapy (NCT). This study aimed to evaluate percent changes in volumetric breast density (ΔVbd%) before and after NCT measured automatically and determine its value as a predictive marker of pathological response to NCT. Materials and Methods: A total of 357 patients with breast cancer treated between January 2014 and December 2016 were included. An automated volumetric breast density (Vbd) measurement method was used to calculate Vbd on mammography before and after NCT. Patients were divided into three groups according to ΔVbd%, calculated as follows: Vbd (post-NCT - pre-NCT)/pre-NCT Vbd × 100 (%). The stable, decreased, and increased groups were defined as -20% ≤ ΔVbd% ≤ 20%, ΔVbd% < -20%, and ΔVbd% > 20%, respectively. Pathological complete response (pCR) was considered to be achieved after NCT if there was no evidence of invasive carcinoma in the breast or metastatic tumors in the axillary and regional lymph nodes on surgical pathology. The association between ΔVbd% grouping and pCR was analyzed using univariable and multivariable logistic regression analyses. Results: The interval between the pre-NCT and post-NCT mammograms ranged from 79 to 250 days (median, 170 days). In the multivariable analysis, ΔVbd% grouping (odds ratio for pCR of 0.420 [95% confidence interval, 0.195-0.905; P = 0.027] for the decreased group compared with the stable group), N stage at diagnosis, histologic grade, and breast cancer subtype were significantly associated with pCR. This tendency was more evident in the luminal B-like and triple-negative subtypes. Conclusion: ΔVbd% was associated with pCR in breast cancer after NCT, with the decreased group showing a lower rate of pCR than the stable group. Automated measurement of ΔVbd% may help predict the NCT response and prognosis in breast cancer.

키워드

과제정보

This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2019-0168). This work was also supported by the Korea Medical Device Development Fund grant funded by the Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, Republic of Korea, the Ministry of Food and Drug Safety) (Project Number: KMDF202011A01-04) and MSIT (NRF-2021R1A2C3006264).

참고문헌

  1. Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019;30:1541-1557 https://doi.org/10.1093/annonc/mdz235
  2. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-172 https://doi.org/10.1016/S0140-6736(13)62422-8
  3. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012;19:1508-1516 https://doi.org/10.1245/s10434-011-2108-2
  4. Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2013). J Natl Cancer Inst Monogr 2015;2015:90-96 https://doi.org/10.1093/jncimonographs/lgv023
  5. Rubovszky G, Horvath Z. Recent advances in the neoadjuvant treatment of breast cancer. J Breast Cancer 2017;20:119-131 https://doi.org/10.4048/jbc.2017.20.2.119
  6. Chen JH, Gulsen G, Su MY. Imaging breast density: established and emerging modalities. Transl Oncol 2015;8:435-445 https://doi.org/10.1016/j.tranon.2015.10.002
  7. Vinnicombe SJ. Breast density: why all the fuss? Clin Radiol 2018;73:334-357 https://doi.org/10.1016/j.crad.2017.11.018
  8. Andersson TM, Crowther MJ, Czene K, Hall P, Humphreys K. Mammographic density reduction as a prognostic marker for postmenopausal breast cancer: results using a joint longitudinal-survival modeling approach. Am J Epidemiol 2017;186:1065-1073 https://doi.org/10.1093/aje/kwx178
  9. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:2086-2092 https://doi.org/10.1158/1055-9965.EPI-06-0345
  10. Jang HJ, Kim HJ, Chae YS, Lee SJ, Kim SH, Lee H, et al. Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement. Eur Radiol 2020;30:4785-4794 https://doi.org/10.1007/s00330-020-06830-9
  11. Eriksson L, He W, Eriksson M, Humphreys K, Bergh J, Hall P, et al. Adjuvant therapy and mammographic density changes in women with breast cancer. JNCI Cancer Spectr 2018;2:pky071
  12. Skarping I, Fornvik D, Heide-Jorgensen U, Sartor H, Hall P, Zackrisson S, et al. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients. Cancer Causes Control 2021;32:251-260 https://doi.org/10.1007/s10552-020-01379-w
  13. Ekpo EU, McEntee MF. Measurement of breast density with digital breast tomosynthesis--a systematic review. Br J Radiol 2014;87:20140460
  14. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-2795 https://doi.org/10.1200/JCO.2009.25.6529
  15. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update summary. J Oncol Pract 2018;14:437-441 https://doi.org/10.1200/JOP.18.00206
  16. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 2011;127:591-599 https://doi.org/10.1007/s10549-010-1028-3
  17. Jeffreys M, Warren R, Highnam R, Smith GD. Initial experiences of using an automated volumetric measure of breast density: the standard mammogram form. Br J Radiol 2006;79:378-382 https://doi.org/10.1259/bjr/24769358
  18. Skarping I, Fornvik D, Heide-Jorgensen U, Sartor H, Hall P, Zackrisson S, et al. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast 2020;53:33-41 https://doi.org/10.1016/j.breast.2020.05.013
  19. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628 https://doi.org/10.1093/jnci/djh106
  20. Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, et al. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst 2015;107:dju425
  21. Kim J, Han W, Moon HG, Ahn S, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012;14:R102
  22. Aktepe F, Kapucuog˘lu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 1996;29:63-67 https://doi.org/10.1046/j.1365-2559.1996.d01-485.x
  23. Skarping I, Fornvik D, Sartor H, Heide-Jorgensen U, Zackrisson S, Borgquist S. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. BMC Cancer 2019;19:1272
  24. Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH, et al. Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. Radiology 2016;279:710-719 https://doi.org/10.1148/radiol.2015151261
  25. Youk JH, Gweon HM, Son EJ, Kim JA. Automated volumetric breast density measurements in the era of the BI-RADS fifth edition: a comparison with visual assessment. AJR Am J Roentgenol 2016;206:1056-1062 https://doi.org/10.2214/AJR.15.15472
  26. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015;150:127-139 https://doi.org/10.1007/s10549-015-3287-5
  27. Iwase T, Sangai T, Nagashima T, Sakakibara M, Sakakibara J, Hayama S, et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 2016;5:41-48 https://doi.org/10.1002/cam4.571
  28. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-2578 https://doi.org/10.1158/1055-9965.EPI-09-0372